NASDAQ:LMAT • US5255582018
The current stock price of LMAT is 87.66 USD. In the past month the price increased by 1.34%. In the past year, price decreased by -11.14%.
ChartMill assigns a technical rating of 4 / 10 to LMAT. When comparing the yearly performance of all stocks, LMAT is a bad performer in the overall market: 74.38% of all stocks are doing better.
ChartMill assigns a fundamental rating of 7 / 10 to LMAT. LMAT scores excellent points on both the profitability and health parts. This is a solid base for a good stock.
Over the last trailing twelve months LMAT reported a non-GAAP Earnings per Share(EPS) of 2.19. The EPS increased by 19.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 22.14% | ||
| ROA | 8.92% | ||
| ROE | 14.08% | ||
| Debt/Equity | 0.44 |
17 analysts have analysed LMAT and the average price target is 105.74 USD. This implies a price increase of 20.63% is expected in the next year compared to the current price of 87.66.
For the next year, analysts expect an EPS growth of 27.49% and a revenue growth 12.78% for LMAT
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 19.62 | 193.832B | ||
| ISRG | INTUITIVE SURGICAL INC | 47.53 | 169.664B | ||
| SYK | STRYKER CORP | 24.21 | 139.908B | ||
| BSX | BOSTON SCIENTIFIC CORP | 21.34 | 109.921B | ||
| BDX | BECTON DICKINSON AND CO | 11.16 | 50.66B | ||
| IDXX | IDEXX LABORATORIES INC | 42.48 | 49.283B | ||
| EW | EDWARDS LIFESCIENCES CORP | 25.52 | 44.358B | ||
| RMD | RESMED INC | 20.57 | 35.869B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16 | 35.845B | ||
| DXCM | DEXCOM INC | 27.73 | 25.383B |
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
LeMaitre Vascular, Inc. engages in the provision of medical devices and human tissue cryopreservation services. The company is headquartered in Burlington, Massachusetts and currently employs 651 full-time employees. The company went IPO on 2006-10-19. The firm develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and other specialties, such as cardiac surgeons, general surgeons, and neurosurgeons. Its portfolio of product lines is used to treat vascular disease, which used in open vascular surgery and dialysis access. The company also offers human vascular and cardiac tissue cryopreservation services. Its principal product lines include anastomotic clips, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy and occlusion catheters, radiopaque marking tape, synthetic vascular and dialysis grafts, and valvulotomes. Its principal biologic offerings include vascular and cardiac patches as well as vascular and dialysis grafts. Its product offerings are sold primarily in the United States, Europe, Canada, and Asia Pacific.
LEMAITRE VASCULAR INC
63 2nd Ave
Burlington MASSACHUSETTS 01803 US
CEO: George W. LeMaitre
Employees: 651
Phone: 18009279800
LeMaitre Vascular, Inc. engages in the provision of medical devices and human tissue cryopreservation services. The company is headquartered in Burlington, Massachusetts and currently employs 651 full-time employees. The company went IPO on 2006-10-19. The firm develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and other specialties, such as cardiac surgeons, general surgeons, and neurosurgeons. Its portfolio of product lines is used to treat vascular disease, which used in open vascular surgery and dialysis access. The company also offers human vascular and cardiac tissue cryopreservation services. Its principal product lines include anastomotic clips, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy and occlusion catheters, radiopaque marking tape, synthetic vascular and dialysis grafts, and valvulotomes. Its principal biologic offerings include vascular and cardiac patches as well as vascular and dialysis grafts. Its product offerings are sold primarily in the United States, Europe, Canada, and Asia Pacific.
The current stock price of LMAT is 87.66 USD. The price increased by 1.22% in the last trading session.
LEMAITRE VASCULAR INC (LMAT) has a dividend yield of 0.92%. The yearly dividend amount is currently 0.64.
LMAT has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
LEMAITRE VASCULAR INC (LMAT) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
LEMAITRE VASCULAR INC (LMAT) currently has 651 employees.
LEMAITRE VASCULAR INC (LMAT) will report earnings on 2026-02-19, after the market close.